Intrathecal Administration of Expanded Wharton's Jelly Mesenchymal Stem Cells in Chronic Traumatic Spinal Cord Injury
Status:
Completed
Trial end date:
2020-02-11
Target enrollment:
Participant gender:
Summary
This is a phase I/IIa, randomized, double-blind, two-arms, two-dose administration, placebo
controlled, two-way crossover clinical trial in which 10 patients from 18 to 65 years of age
affected with chronic traumatic spinal cord will enter the study with the objective to assess
the safety and to obtain efficacy data in intrathecal administration of expanded Wharton's
jelly mesenchymal stem cells.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Banc de Sang i Teixits
Collaborators:
Hospital de Neurorehabilitació Institut Guttmann Recerca Clínica S.L. Syntax for Science Syntax for Science, S.L